In this issue:
Empagliflozin in HFPEF
Association of genetic variants with nonischaemic DCM outcomes
Outpatient management of HF during the COVID-19 pandemic
Ferric carboxymaltose for treating iron deficiency in HF
Integration of imaging and circulating biomarkers in HF
CAD and coronary microvascular dysfunction in HFPEF
Blended collaborative care for HF and comorbid depression
Spironolactone in echocardiographic HFPEF phenotype suggestive of cardiac amyloidosis
Dapagliflozin in patients with kidney disease, with and without HF
Managing HF in non-cardiology settings
Please login below to download this issue (PDF)